Skip to content

The Effects and Mechanisms of Danshen Beverage in Regulating Autophagy-Mediated Cell Death for Interventional Therapy-Induced Restenosis in Coronary Heart Disease

The Effects and Mechanisms of Danshen Beverage in Regulating Autophagy-Mediated Cell Death for Interventional Therapy-Induced Restenosis in Coronary Heart Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000028
Enrollment
Unknown
Registered
2024-03-15
Start date
2022-04-08
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary heart disease

Interventions

Treatment group:In addition to the conventional Western medicine treatment received by the control group, the intervention group is given Danshen drink as an oral traditional Chinese medicine. The Dan
Control group:Conventional Western medicine treatment. Preoperatively, administer clopidogrel 75 mg/d and aspirin 100 mg/d. If there are no contraindications, continue with the standard maintenance af

Sponsors

Guangdong Provincial Hospital of Chinese Medicine Zhuhai Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) Conforming to the diagnostic criteria of both Chinese and Western medicine. (2) Meeting the indications for PCI and agreeing to undergo coronary stent implantation. Patients who experience recurrent chest pain or discomfort after the procedure and can return to the hospital for coronary angiography (CAG) re-examination. (3) Capable of completing 1 year of treatment post-surgery and complying with the observation indicators. (4) Age between 18 and 85 years with normal expressive and communication abilities. (5) Selected cases must obtain informed consent from the patients.

Exclusion criteria

Exclusion criteria: (1) Patients with concomitant chronic kidney disease and severe dysfunction of important organs such as heart, lungs, liver, etc.; those with severe primary diseases like hematopoietic system and endocrine system disorders, malignant tumors, uncontrolled systemic infections, or other conditions that are expected to prevent completion of the trial. (2) Patients who have previously undergone coronary artery bypass grafting surgery, type 1 diabetes patients, and patients with acute myocardial infarction undergoing emergency PCI. (3) Patients who are contraindicated for coronary angiography and those who cannot receive antiplatelet aggregation drugs for various reasons, as well as patients who experience severe cardiovascular events following PCI. (4) Patients unable to cooperate due to mental or psychological disorders. (5) Pregnant or breastfeeding women, or those planning to become pregnant.

Design outcomes

Primary

MeasureTime frame
Evaluate coronary artery blood flow using coronary CT angiography (CTA) or coronary angiography 1 year postoperatively;

Secondary

MeasureTime frame
Cardiac enzymes;Lipid profile;Echocardiogram;Myoglobin;Troponin;Electrocardiogram;Seattle Angina Questionnaire score;

Countries

China

Contacts

Public ContactLiu Qing

53 Jingle Road, Xiangzhou District, Zhuhai City, Guangdong Province

851757626@qq.com+86 136 3122 3512

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026